APPLICATION
ANDA211835
TYPE
ANDA
ORIGINAL APPROVAL
2020-10-21
LATEST ACTION
2022-08-12
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
APREPITANTPrescription
APREPITANT 125MG · CAPSULE · ORAL
APREPITANTPrescription
APREPITANT 40MG · CAPSULE · ORAL
APREPITANTPrescription
APREPITANT 80MG · CAPSULE · ORAL
Approval history
2022-08-12Labeling · Supplement 1 · standardAP
2020-10-21UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.